Genomic alterations in Hodgkin's lymphoma

International Journal of Hematology

Volumn 83, Issue 5, 2006, Pages 379-384

  Weniger, Marc A ^a   Barth, Thomas F E ^a   Möller, Peter ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Chromosomal aberration; Cytogenetics; Epigenetics; Genomic instability; Hodgkin's lymphoma; Translocation

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CHROMOSOME 2P; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CLASSICAL HODGKIN LYMPHOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCUS; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LYMPHOMA CELL LINE; MICRODISSECTION; MOLECULAR GENETICS; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NUMERICAL CHROMOSOME ABERRATION;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 9; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMANS; LYMPHOMA, B-CELL; NUCLEIC ACID HYBRIDIZATION;

EID: 33751030328     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06048     Document Type: Article

References (94)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005;105:4051-4059.
3. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540-550.
4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.
5. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001;38:368-375.
6. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma. 2000;38:363-371.
7. Oshima Y, Puri RK. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol. 2001;211:37-42.
8. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol. 2002;13(suppl 1): 52-56.
9. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol. 2002;55:162-176.
10. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol. 2005;23:6379-6386.
11. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005;105:4553-4560.
12. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res. 2002;84:277-312.
13. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
14. Yonetani N, Kurata M, Nishikori M, et al. Primary mediastinal large B-cell lymphoma: a comparative study with nodular sclerosis-type Hodgkin's disease. Int J Hematol. 2001;74:178-185.
15. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-1421.
16. Poppema S, Kluiver JL, Atayar C, et al. Report: workshop on mediastinal grey zone lymphoma. Eur J Haematol Suppl. 2005:45-52.
17. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220-1235.
18. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623-627.
19. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-649.
20. Gollin SM. Chromosomal instability. Curr Opin Oncol. 2004;16:25-31.
21. Gollin SM. Mechanisms leading to chromosomal instability. Semin Cancer Biol. 2005;15:33-42.
22. Re D, Zander T, Diehl V, Wolf J. Genetic instability in Hodgkin's lymphoma. Ann Oncol. 2002;13(suppl 1):19-22.
23. Saunders W. Centrosomal amplification and spindle multipolarity in cancer cells. Semin Cancer Biol. 2005;15:25-32.
24. Kramer A, Neben K, Ho AD. Centrosome aberrations in hematological malignancies. Cell Biol Int. 2005;29:375-383.
25. Kramer A, Schweizer S, Neben K, et al. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma. Leukemia. 2003;17:2207-2213.
26. Falzetti D, Crescenzi B, Matteuci C, et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica. 1999;84:298-305.
27. + Hodgkin cells. Cancer Res. 2000;60:549-552.
28. Martin-Subero JI, Knippschild U, Harder L, et al. Segmental chromosomal aberrations and centrosome amplifications: pathogenetic mechanisms in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma? Leukemia. 2003;17:2214-2219.
29. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58: 3974-3985.
30. Joos S, Granzow M, Holtgreve-Grez H, et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 2003;103: 489-495.
31. Duval A, Raphael M, Brennetot C, et al. The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A. 2004;101:5002-5007.
32. Re D, Benenson L, Wickenhauser C, et al. Proficient mismatch repair protein expression in Hodgkin and Reed Sternberg cells. Int J Cancer. 2002;97:205-210.
33. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96:808-822.
34. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580-5594.
35. Vanasse GJ, Concannon P, Willerford DM. Regulated genomic instability and neoplasia in the lymphoid lineage. Blood. 1999;94: 3997-4010.
36. Gravel S, Delsol G, Al Saati T. Single-cell analysis of the t(14;18) (q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells. Blood. 1998;91:2866-2874.
37. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood. 1996;88:1771-1779.
38. Chaganti SR, Chen W, Parsa N, et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer. 1998;23:323-327.
39. Ohno H. Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma. Histol Histopathol. 2004;19:637-650.
40. Jardin F, Ruminy P, Parmentier F, et al. Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma. Leukemia. 2005;19:1824-1830.
41. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6:1054-1060.
42. Jardin F, Sahota SS. Targeted somatic mutation of the BCL6 protooncogene and its impact on lymphomagenesis. Hematology. 2005; 10:115-129.
43. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003;101:706-710.
44. Renne C, Martin-Subero JI, Hansmann ML, Siebert R. Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition. J Mol Diagn. 2005;7:352-356.
45. Chui DT, Hammond D, Baird M, Shield L, Jackson R, Jarrett RF. Classical Hodgkin lymphoma is associated with frequent gains of 17q. Genes Chromosomes Cancer. 2003;38:126-136.
46. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99:1381-1387.
47. Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101: 3681-3686.
48. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005;24:8259-8267.
49. Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 2005;65:439-447.
50. Barth TF, Bentz M, Leithauser F, et al. Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer. 2001;31:316-325.
51. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 2001; 30:393-401.
52. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87:1571-1578.
53. Goldin LR, McMaster ML, Ter-Minassian M, et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J Med Genet. 2005;42: 595-601.
54. Gebhart E. Genomic imbalances in human leukemia and lymphoma detected by comparative genomic hybridization (review). Int J Oncol. 2005;27:593-606.
55. Ohshima K, Haraoka S, Yoshioka S, et al. Chromosome 16q deletion and loss of E-cadherin expression in Hodgkin and Reed-Sternberg cells. Int J Cancer. 2001;92:678-682.
56. Re D, Starostik P, Massoudi N, et al. Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells. Cancer Res. 2003;63: 2606-2609.
57. Lespinet V, Terraz F, Recher C, et al. Single-cell analysis of loss of heterozygosity at the ATM gene locus in Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma: ATM loss of heterozygosity is a rare event. Int J Cancer. 2005;114:909-916.
58. Maggio EM, van den Berg A, de Jong D, Diepstra A, Poppema S. Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. Am J Pathol. 2003;162:29-35.
59. Franke S, Wlodarska I, Maes B, et al. Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood. 2001;97:1845-1853.
60. Rodig SJ, Savage KJ, Nguyen V, et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol. 2005;29:196-203.
61. Xiao Q, Shen N, Hedvat CV, et al. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2004; 12:211-215.
62. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212.
63. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99:1474-1477.
64. Liu P, Keller JR, Ortiz M, et al. Bcl11a is essential for normal lymphoid development. Nat Immunol. 2003;4:525-532.
65. Kuppers R, Sonoki T, Satterwhite E, et al. Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14) (p13;q32) translocation involving the BCL11A gene. Leukemia. 2002;16:937-939.
66. Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001; 98:3413-3420.
67. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900-911.
68. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006;18: 449-455.
69. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99: 618-626.
70. O'Shea JJ, Watford W. A peek at PIAS. Nat Immunol. 2004;5: 875-876.
71. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004;103: 4630-4635.
72. Chim CS, Wong KY, Loong F, Srivastava G. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia. 2004;18:356-358.
73. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105: 2535-2542.
74. Melzner I, Weniger MA, Bucur AJ, et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer. 2006;118:1941-1944.
75. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STATS accumulation. Oncogene. 2006;25:2679-2684.
76. Baus D, Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer. 2006;118:1404-1413.
77. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell. 2002;2:9-15.
78. Kupper M, Joos S, von Bonin F, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol. 2001;112:768-775.
79. Sanchez-Aguilera A, Garcia JF, Sanchez-Beato M, Piris MA. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene. 2006; 25:2565-2574.
80. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20:1-13.
81. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(suppl 1):S4-S11.
82. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p161NK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am J Pathol. 2002;161: 1007-1013.
83. Murray PG, Qiu GH, Fu L, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene. 2004;23:1326-1331.
84. INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood. 2004;103:2351-2357.
85. Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood. 2004;104:3326-3334.
86. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107:2493-2500.
87. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.
88. Raaphorst FM. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet. 2005;14(spec no 1):R93-R100.
89. Vire E, Brenner C. Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439: 871-874.
90. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol. 2004;164:873-881.
91. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005;65:3509-3512.
92. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376-385.
93. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243-249.
94. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102:3627-3632.